Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Zoetis Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 40.5× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Zoetis Inc pays a 2.9% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Zoetis Inc for 70 Days on average.
| FEPI | ZTS | |
|---|---|---|
Market Cap | $746.48M | $30.20B |
Volume | 334,337 | 6,175,327 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $147.53 |
52-Week Low | $37.98 | $69.09 |
Typical Hold Time | 56 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $43.51, down 0.18% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF employs a covered call strategy on AI and tech stocks, generating high weekly dividends but facing capped upside. Recent news highlights its 25% yield but notes underperformance versus peers in total return.
The outlook is mixed: high income appeals, but concentration in volatile tech and covered call limitations pose risks. Investors seeking yield may find value, yet must weigh potential underperformance if tech momentum slows. Risks include sector volatility and strategy constraints in rising markets.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
